title: The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.
abstract: Tumors usurp established metabolic steps used by normal tissues for glucose utilization and ATP production that rely heavily on mitochondria and employ a route that, although involving mitochondria, includes a much greater dependency on glycolysis. First described by Otto Warburg almost nine decades ago [1], this aberrant phenotype becomes more pronounced with increased tumor malignancy [2]. Thus, while maintaining their capacity for respiration, tumors "turn more parasitic" by enhancing their ability to scavenge glucose from their surroundings. With excess glucose at hand, tumors shunt their metabolic flux more toward glycolysis than do their normal cells of origin, a strategy that allows for their survival when oxygen is limiting while providing them a mechanism to poison their extra-cellular environment with acid, thus paving the way for invasion and metastasis. Significantly, tumors harness a crucial enzyme to regulate and support this destructive path--to entrap and channel glucose toward glycolysis. This enzyme is an isoform of hexokinase, referred to as hexokinase type II, and also in abbreviated form as HK-2 or HK II. Due to many-faceted molecular features at genetic, epigenetic, transcriptional, and enzymatic levels, including sub-cellular localization to mitochondria, HK-2 facilitates and promotes the high glycolytic tumor phenotype [3]. Thus, HK-2 represents a pivotal model gene or enzyme that tumors "select for" during tumorigenesis in order to facilitate their destructive path. In this review, we examine the roles played by mitochondrial bound HK-2 within the context of the highly choreographed metabolic roulette of malignant tumors. Recent studies that outline how the aberrant glycolytic flux can be subverted toward a more "normal" metabolic phenotype, and how the glycolytic flux affects the tumor microenvironment to facilitate tumor dissemination are also described, including how these very features can be harnessed in new metabolic targeting strategies to selectively debilitate tumors.
authors.affiliation: Department of Neurological Surgery and Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
authors.forename: Saroj P
authors.initials: SP
authors.lastname: Mathupala
authors.forename: Young H
authors.initials: YH
authors.lastname: Ko
authors.forename: Peter L
authors.initials: PL
authors.lastname: Pedersen
mesh_terms: D000818:Animals; D005947:Glucose / Q000378:metabolism; D006019:Glycolysis; D006593:Hexokinase / Q000235:genetics / Q000378:metabolism; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D019344:Lactic Acid; D008928:Mitochondria / Q000378:metabolism*; D008954:Models, Biological; D027501:Monocarboxylic Acid Transporters / Q000378:metabolism; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D017494:Proton Pumps / Q000378:metabolism; D012106:Research / Q000266:history
chemical_list: D027501:Monocarboxylic Acid Transporters; D017494:Proton Pumps; D019344:Lactic Acid; D006593:Hexokinase; D005947:Glucose
references.citation: Prog Exp Tumor Res. 1978;22:190-274
references.pmid: 149996
references.citation: Biochim Biophys Acta. 2002 Sep 10;1555(1-3):14-20
references.pmid: 12206885
references.citation: Pflugers Arch. 2009 Sep;458(5):981-92
references.pmid: 19437033
references.citation: Cancer Res. 1996 Jun 1;56(11):2468-71
references.pmid: 8653677
references.citation: Curr Med Chem. 2009;16(13):1561-87
references.pmid: 19442134
references.citation: Biochem Biophys Res Commun. 2004 Nov 5;324(1):269-75
references.pmid: 15465013
references.citation: Eur J Biochem. 1975 Jun 16;55(1):315-21
references.pmid: 1175605
references.citation: Ann N Y Acad Sci. 1986;488:438-50
references.pmid: 3555259
references.citation: Adv Exp Med Biol. 1977 May 22-24;92:363-80
references.pmid: 205103
references.citation: Arch Biochem Biophys. 1996 May 1;329(1):17-23
references.pmid: 8619630
references.citation: J Bioenerg Biomembr. 2008 Jun;40(3):123-6
references.pmid: 18780167
references.citation: Eur J Cell Biol. 2008 Sep;87(8-9):591-9
references.pmid: 18328592
references.citation: Int J Cancer. 1995 Jul 17;62(2):216-22
references.pmid: 7622299
references.citation: Biol Res. 2002;35(1):9-26
references.pmid: 12125211
references.citation: Cell. 2008 Sep 5;134(5):703-7
references.pmid: 18775299
references.citation: Cancer Cell. 2007 Jan;11(1):37-51
references.pmid: 17222789
references.citation: Radiother Oncol. 2009 Sep;92(3):329-33
references.pmid: 19604589
references.citation: AJNR Am J Neuroradiol. 1983 May-Jun;4(3):826-9
references.pmid: 6308993
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50
references.pmid: 18032601
references.citation: Cancer Res. 1988 Feb 15;48(4):913-9
references.pmid: 3338084
references.citation: J Biol Chem. 2001 Nov 16;276(46):43407-12
references.pmid: 11557773
references.citation: Cancer Res. 2009 Mar 15;69(6):2260-8
references.pmid: 19276390
references.citation: Pflugers Arch. 2004 Feb;447(5):619-28
references.pmid: 12739169
references.citation: Eur J Biochem. 2002 Jul;269(13):3226-36
references.pmid: 12084063
references.citation: J Biol Chem. 1981 Aug 25;256(16):8699-704
references.pmid: 7263678
references.citation: J Biol Chem. 2003 Apr 25;278(17):15333-40
references.pmid: 12566445
references.citation: Oncogene. 2006 Aug 7;25(34):4777-86
references.pmid: 16892090
references.citation: Science. 2009 May 22;324(5930):1029-33
references.pmid: 19460998
references.citation: Neurosurgery. 2006 Dec;59(6):1313-23; discussion 1323-4
references.pmid: 17277695
references.citation: Anticancer Res. 2006 Sep-Oct;26(5A):3561-6
references.pmid: 17094483
references.citation: Rev Physiol Biochem Pharmacol. 1995;126:65-198
references.pmid: 7886381
references.citation: Br J Cancer. 2008 Oct 7;99(7):989-94
references.pmid: 18766181
references.citation: J Biol Chem. 1995 Jul 14;270(28):16918-25
references.pmid: 7622509
references.citation: J Cancer Res Clin Oncol. 2009 Jul;135(7):867-77
references.pmid: 19415328
references.citation: J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S
references.pmid: 18523064
references.citation: J Biol Chem. 1997 Sep 5;272(36):22776-80
references.pmid: 9278438
references.citation: J Bioenerg Biomembr. 2007 Jun;39(3):211-22
references.pmid: 17879147
references.citation: Arch Biochem Biophys. 1995 Jan 10;316(1):206-14
references.pmid: 7840618
references.citation: Ann Neurol. 1984;15 Suppl:S138-46
references.pmid: 6331282
references.citation: Curr Genomics. 2007 Apr;8(2):113-28
references.pmid: 18660845
references.citation: Oncogene. 2006 Aug 7;25(34):4787-97
references.pmid: 16892091
references.citation: Cancer Res. 2006 May 15;66(10):5216-23
references.pmid: 16707446
references.citation: Biochem J. 1994 Oct 1;303 ( Pt 1):269-74
references.pmid: 7945251
references.citation: Science. 1956 Aug 10;124(3215):269-70
references.pmid: 13351639
references.citation: Cell Metab. 2006 Mar;3(3):177-85
references.pmid: 16517405
references.citation: Proc Natl Acad Sci U S A. 1977 Sep;74(9):3735-9
references.pmid: 198801
references.citation: J Exp Biol. 2003 Jun;206(Pt 12):2049-57
references.pmid: 12756287
references.citation: Neurosurgery. 2004 Dec;55(6):1410-9; discussion 1419
references.pmid: 15574223
references.citation: Biochim Biophys Acta. 1994 Nov 22;1219(3):660-8
references.pmid: 7948023
references.citation: Curr Pharm Des. 2008;14(7):685-98
references.pmid: 18336315
references.citation: Semin Cancer Biol. 2009 Feb;19(1):17-24
references.pmid: 19101634
references.citation: Cancer Res. 2003 Jul 15;63(14):3847-54
references.pmid: 12873971
references.citation: Cancer Lett. 2001 Nov 8;173(1):83-91
references.pmid: 11578813
references.citation: Science. 1956 Feb 24;123(3191):309-14
references.pmid: 13298683
references.citation: J Bioenerg Biomembr. 2007 Feb;39(1):73-7
references.pmid: 17354062
references.citation: Cancer Cell. 2006 Jun;9(6):425-34
references.pmid: 16766262